Drug Search Results
More Filters [+]

Devimistat

Alternative Names: devimistat, cpi-613, cpi613, cpi 613
Latest Update: 2024-09-11
Latest Update Note: Clinical Trial Update

Product Description

RafaelÕs lead compound, CPI-613¨Ê(devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. (Sourced from: https://rafaelpharma.com/research-and-development/cpi-613-drug)

Mechanisms of Action: Pyruvate Dehydrogenase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation:
Fast Track - Acute Leukemia|Acute Myeloid Leukemia|Leukemia|Myeloid Leukemia
Fast Track - Pancreatic Cancer
Orphan Drug - Biliary Tract Cancer
Orphan Drug - Lymphoma|Burkitt Lymphoma
Orphan Drug - Sarcoma *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Rafael Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Devimistat

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Adenocarcinoma|Pancreatic Cancer

Phase 2: Clear Cell Sarcoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CCS618

P2

Completed

Clear Cell Sarcoma

2023-03-09

PANC003 (also known as “AVENGER 500”)

P3

Active, not recruiting

Pancreatic Cancer|Adenocarcinoma

2022-05-07

Recent News Events